Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 3)

Clinical trial NCT04932187 · UNKNOWN

Trial details

NCT number: NCT04932187
Sponsor: Ruijin Hospital
Status: UNKNOWN
Phase: Phase 1
Study type: INTERVENTIONAL

Hepatobiliary, Pancreatic and Other Gastrointestinal Carcinoma (Non-stomach, Non-esophagi)

Start date: 2021-08-01
Primary completion: 2023-07-01
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.